WikiStock

Global Securities Firms Regulatory Inquiry App

English
Download
Home-News-

<Research>G Sachs Trims TPs on Medicals Broadly; Investors Still Eye on Anti-corruption Impact

iconAASTOCKS

2024-07-19 11:32

Goldman Sachs released a report. Ahead of the 2Q24 and 1H24 results season, the TPs on the whole line of health care related stocks were cut, with the...

  Goldman Sachs released a report. Ahead of the 2Q24 and 1H24 results season, the TPs on the whole line of health care related stocks were cut, with the average range of about 9%. The broker also lowered its industry sales estimates for FY2024-25 by 1%-15% and 1%-16%. The broker believed that investors will remain centered on the impact of from anti-corruption, roll-out of the central procurement policies and potential stimulus from trade-in program.

  Goldman Sachs' ratings and TPs for pharmaceuticals are listed below:

  Related NewsNomura Chops HYGEIA HEALTH (06078.HK) TP to $50.7, Cuts Rev./ Earnings Forecasts

  Stocks | Ratings| Target Prices

  WEIGAO GROUP (01066.HK) -0.180 (-4.276%) Short selling $5.80M; Ratio 17.469% | Buy | $8.7 -> $7.8

  KANGJI MEDICAL (09997.HK) -0.050 (-0.893%) Short selling $150.37K; Ratio 20.905% | Buy | $11.2 -> $10.6

  Related NewsM Stanley Expects Medtechs to Report Weak 2Q24 Results; TPs Adjusted

  AK MEDICAL (01789.HK) -0.060 (-1.304%) Short selling $218.38K; Ratio 15.168% | Buy | $8.9 -> $8.2

  HYGEIA HEALTH (06078.HK) -1.100 (-3.971%) Short selling $5.07M; Ratio 29.449% | Buy | $50 -> $46

  HEARTCARE-B (06609.HK) -0.080 (-0.485%) | Buy | $29.8 -> $25.6

  GUSHENGTANG (02273.HK) -0.350 (-0.927%) Short selling $1.33M; Ratio 16.594% | Buy | $61 -> $60

  MICROTECH MED-B (02235.HK) -0.110 (-2.933%) | Sell | $5.7 -> $5

  JXR (01951.HK) -0.200 (-6.873%) Short selling $15.12M; Ratio 29.856% | Neutral | $3.39 -> $3.2

  VENUS MEDTECH-B (02500.HK) 0.000 (0.000%) | Neutral | $6 -> $5.6

  (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-07-19 12:25.)

  AAStocks Financial News

Disclaimer:The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.